From L-R: Latus CSO Jang-Ho Cha, Latus CEO Peter Ghoroghchian and co-founder Beverly Davidson
Exclusive: Spark co-founder launches new CNS gene therapy biotech with $54M
Jang-Ho Cha had no interest in leaving his post at Novartis, where he led translational medicine for the pharma giant’s work in neuroscience.
But in …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
